โ Scribed by Susanna Wu-Pong (auth.), Susanna Wu-Pong PhD, Yon Rojanasakul PhD (eds.)
No coin nor oath required. For personal study only.
Biopharmaceutical Drug Design and Development, Second Edition, updates the widely successful first edition, published in 1999. This new, expanded edition investigates the dozens of new biopharmaceutical drugs that have become available since the publication of the first edition. Among the drugs discussed are ones in the categories of monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, and immonotherapies including vaccines. Additionally, the volume examines new and emerging technologies, such as bioinformatics, DNA microarrays, transgenics, therapeutic gene delivery, stem cells, nucleic acid-based therapeutics, and macromolecular drug delivery. Authors also study pharmacogenetics in the clinic and changes in biologic drug approval at the FDA. Biopharmaceutical Drug Design and Development, Second Edition, is a worthy sequel in the discussion on the dynamic, exciting field of biotechnology.
Front Matter....Pages i-x
Biotechnology: 2008 and Beyond....Pages 1-14
The Human Genome Project and Drug Development....Pages 15-29
The Use of Bioinformatics and Chemogenomics in Drug Discovery....Pages 31-45
DNA Microarrays in Drug Discovery and Development....Pages 47-66
Microarray Technology Using Proteins, Cells, and Tissues....Pages 67-97
Pharmacogenetic Issues in Biopharmaceutical Drug Development....Pages 99-120
Development and Applications of Transgenics in Biotechnology and Medicine....Pages 121-139
Viral, Nonviral, and Physical Methods for Gene Delivery....Pages 141-173
Stem Cell Technology and Drug Development....Pages 175-191
Small Nucleic Acid-Based Drugs: Successes and Pitfalls....Pages 193-221
Therapeutic Strategies Targeting the Innate Antiviral Immune Response....Pages 223-251
Pharmacogenetics in the Clinic....Pages 253-266
Molecular Modeling: Considerations for the Design of Pharmaceuticals and Biopharmaceuticals....Pages 267-291
Macromolecular Drug Delivery....Pages 293-323
Changes in Biologic Drug Approval at FDA....Pages 325-343
Follow-On Protein Products: The Age of Biogenerics?....Pages 345-366
Back Matter....Pages 367-375
Pharmacology/Toxicology; Cell Biology; Biochemistry, general; Pharmacy
๐ SIMILAR VOLUMES
This book provides a comprehensive examination of the newest biopharmaceutical drugs. Among the drugs discussed are ones in the categories of monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, and immonotherapies including vaccines. Additional
<p><p>This volume explores the application of Quality by Design (QbD) to biopharmaceutical drug product development. Twenty-eight comprehensive chapters cover dosage forms, liquid and lyophilized drug products. The introductory chapters of this book define key elements of QbD and examine how these e
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. <br> Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is
In the last two decades, the discipline of biopharmaceutics has undergone considerable advances, particularly with regard to bioavailability and bioequivalence as they relate to product quality and regulatory standards of approval. Textbooks in the field have not been able to keep up with the growth
In the last two decades, the discipline of biopharmaceutics has undergone considerable advances, particularly with regard to bioavailability and bioequivalence as they relate to product quality and regulatory standards of approval. Textbooks in the field have not been able to keep up with the growth